Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment

X
Trial Profile

A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Certolizumab pegol (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary) ; Triamcinolone (Primary) ; Azathioprine; Corticosteroids; Glucocorticoids; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Prednisolone; Prednisone; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms NORD-STAR
  • Most Recent Events

    • 15 Nov 2023 Results of post hoc analysis (n=330) presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of 48 Week Patient-reported Outcomes , presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of a spin-off study from main NORD-STAR study assessing effects of different initial treatments on NET formation in patients with early RA presented at the ACR Convergence 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top